Philogen SpA (MIL:PHIL) EBIT : €-29.40 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA EBIT?

Philogen SpA's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-15.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-29.40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Philogen SpA's annualized ROC % for the quarter that ended in Jun. 2024 was -102.07%. Philogen SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -118.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Philogen SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -3.98%.

Philogen SpA EBIT Historical Data

The historical data trend for Philogen SpA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA EBIT Chart

Philogen SpA Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-12.02

-14.84

-3.95

-5.63

Philogen SpA Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial				3.64	-7.59	8.51	-14.15	-15.26

Competitive Comparison of Philogen SpA's EBIT

For the Biotechnology subindustry, Philogen SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Philogen SpA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Philogen SpA's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Philogen SpA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-29.40 Mil.

Philogen SpA (MIL:PHIL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Philogen SpA's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-34.096 * ( 1 - -0.05% )	/	( (34.167	+	32.676)	/ 2 )
=	-34.113048	/	33.4215
=	-102.07 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	119.27	-	9.759	-	( 75.344	-	max(0, 12.71	-	89.236	+	75.344	))
=	34.167

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	104.775	-	11.208	-	( 64.609	-	max(0, 14.432	-	75.323	+	64.609	))
=	32.676

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Philogen SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-30.514	/	( ( (25.876 + max(0.27400000000001, 0))	+	(25.461 + max(-3.011, 0)) )	/	2 )
=	-30.514	/	( ( 26.15	+	25.461 )	/	2 )
=	-30.514	/	25.8055
=	-118.25 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.281	+	2.248	+	8.455)	-	(9.759	+	0	+	1.951)
=	0.27400000000001

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.656	+	2.937	+	5.871)	-	(11.208	+	0	+	1.267)
=	-3.011

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Philogen SpA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-29.403	/	739.178
	=	-3.98 %

Philogen SpA EBIT Related Terms

Thank you for viewing the detailed overview of Philogen SpA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (MIL:PHIL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

78Q:Germany

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.